Search research articles
Contact Us
Filters
Showing results (31-40 of 743) with videos related to
Page
of 75
Sort By:
Current Opinion in Oncology
|
February 10, 2012
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights
Reinhard Dummer, Keith T Flaherty
Oncoimmunology
|
September 20, 2018
Immunological effects of BRAF+MEK inhibition
Paolo A Ascierto, Reinhard Dummer
Current Opinion in Oncology
|
January 23, 2018
Development of encorafenib for BRAF-mutated advanced melanoma
Peter Koelblinger, Olaf Thuerigen, Reinhard Dummer
European Journal of Cancer (Oxford, England : 1990)
|
October 3, 2017
The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients
Alexander M M Eggermont, Reinhard Dummer
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 6, 2007
Cutaneous lymphomas
Reinhard Dummer, Rudolf Stadler, Wolfram Sterry
Archives of Dermatological Research
|
October 9, 2007
Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod
Maja Wuest, Reinhard Dummer, Mirjana Urosevic
Archives of Dermatology
|
March 23, 2005
Dyscrasias with "undetermined significance"
Günter Burg, Reinhard Dummer, Werner Kempf
Experimental Dermatology
|
April 25, 2006
Pathogenesis and therapy of cutaneous lymphomas--progress or impasse?
Reinhard Dummer, Antonio Cozzio, Mirjana Urosevic
Expert Opinion on Investigational Drugs
|
August 10, 2019
Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update
Egle Ramelyte, Reinhard Dummer, Emmanuella Guenova
Future Oncology (London, England)
|
June 8, 2017
A review of binimetinib for the treatment of mutant cutaneous melanoma
Peter Koelblinger, Joelle Dornbierer, Reinhard Dummer
Page
of 75
Search research articles
Search
Showing results (31-40 of 743) with videos related to
Sort By:
Page
of 75
Current Opinion in Oncology
|
February 10, 2012
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights
Reinhard Dummer, Keith T Flaherty
Oncoimmunology
|
September 20, 2018
Immunological effects of BRAF+MEK inhibition
Paolo A Ascierto, Reinhard Dummer
Current Opinion in Oncology
|
January 23, 2018
Development of encorafenib for BRAF-mutated advanced melanoma
Peter Koelblinger, Olaf Thuerigen, Reinhard Dummer
European Journal of Cancer (Oxford, England : 1990)
|
October 3, 2017
The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients
Alexander M M Eggermont, Reinhard Dummer
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 6, 2007
Cutaneous lymphomas
Reinhard Dummer, Rudolf Stadler, Wolfram Sterry
Archives of Dermatological Research
|
October 9, 2007
Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod
Maja Wuest, Reinhard Dummer, Mirjana Urosevic
Archives of Dermatology
|
March 23, 2005
Dyscrasias with "undetermined significance"
Günter Burg, Reinhard Dummer, Werner Kempf
Experimental Dermatology
|
April 25, 2006
Pathogenesis and therapy of cutaneous lymphomas--progress or impasse?
Reinhard Dummer, Antonio Cozzio, Mirjana Urosevic
Expert Opinion on Investigational Drugs
|
August 10, 2019
Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update
Egle Ramelyte, Reinhard Dummer, Emmanuella Guenova
Future Oncology (London, England)
|
June 8, 2017
A review of binimetinib for the treatment of mutant cutaneous melanoma
Peter Koelblinger, Joelle Dornbierer, Reinhard Dummer
Page
of 75